Publications
Click on the publication title to view the
full text (in pdf format).
2011
Innovative use of point-of-care testing for chronic kidney disease screening. Point of Care 2011; 10: 98-101.
Jones GR, Barker G, Goodall I, Schneider HG, Shephard MDS, Twigg SM. Change of HbA1c reporting to SI units. Medical Journal of Australia 2011; 195: 45-46.
Shephard M. Point-of-care testing and creatinine measurement. Clinical Biochemist Reviews 2011; 32: 109-114.
2010
Shephard
M. Point-of-care testing comes of age in Australia. Australian Prescriber
2010; 3: 6-9.
Gialamas
A, Laurence C, Yelland L, Tideman P, Worley P, Shephard M et al. Assessing
agreement between point of care and laboratory results for lipid testing
from a clinical perspective. Clinical Biochemistry 2010; 43: 515-518.
Mathew
T, Corso O, Ludlow M, Boyle A, Cass A, Chadban S, Joyner B, Shephard M,
Usherwood T. Screening for chronic kidney disease in Australia: a pilot
study in the community and workplace. Kidney International 2010; 77 (Supp
116): S9-S16.
Shephard
MD, Peake MJ, Corso O, Shephard AK, Mazzachi BC, Spaeth BA, Mathew TH.
Assessment of the Nova StatSensor whole blood point-of-care creatinine
analyser for the measurement of kidney function in screening for chronic
kidney disease. Clinical Chemistry and Laboratory Medicine 2010; 48: 1113-1119.
Gill
J and Shephard MDS. The conduct of quality control and quality assurance
testing for PoCT outside the laboratory. Clinical Biochemist Reviews 2010;
31: 81-84.
Shephard
MDS and Gill J. The national QAAMS Program – A practical example
of PoCT working in the community. Clinical Biochemist Reviews 2010; 31:
95-99.
2009
Shephard
M. The influence of geography on the performance of quality control testing
in the Australian Government’s Point of Care Testing in General
Practice Trial. Clinical Biochemistry 2009; 42: 1325-1327.
Shephard
M, Shephard A, Watkinson L, Mazzachi B and Worley P. Design, implementation
and results of the Quality Control program for the Australian Government’s
Point of Care Testing in General Practice Trial. Annals of Clinical Biochemistry
2009; 46: 413–419.
Shephard
M, Mazzachi B, Watkinson L, Shephard A, Laurence A, Gialamas A and Bubner
T. Evaluation of a training program for device operators in the Australian
Government’s Point of Care Testing In General Practice Trial. Rural
and Remote Health 2009; 9: 1189. (Online)
2008
Laurence
C, Gialamas A, Yelland L, Bubner T, Ryan P, Willson K, Glastonbury B,
Gill J, Shephard M, Beilby J.. A pragmatic cluster randomised controlled
trial to evaluate the safety, clinical effectiveness, cost effectiveness
and satisfaction with point of care testing in a general practice setting
– rationale, design and baseline characteristics. Trials 2008; 9:50
2007
Shephard
MDS, Mazzachi BC and Shephard AK. Comparative performance of two point-of-care
analysers for lipid testing. Clinical Laboratory 2007; 53: 561-566.
2006
Shephard
M, Allen G, Paizis K, Barbara J, Batterham M and Vanajek A. Results of
an Aboriginal community-based renal disease management program incorporating
point of care testing for urine albumin:creatinine ratio. Rural and Remote
Health 2006; 6: Article 591 (on-line).
Shephard MDS and Gill JP. The
analytical quality of point-of-care testing in the ‘QAAMS’
model for diabetes management in Australian Aboriginal medical services.
Clinical Biochemist Reviews 2006; 27:185-190.
Shephard M. Clinical
and cultural effectiveness of the ‘QAAMS’ point-of-care testing
model for diabetes management in Australian Aboriginal medical services.
Clinical Biochemist Reviews 2006; 27: 161-170.
Shephard M, Mazzachi B, Shephard A, Burgoyne T, Dufek A, Ahkit J, Mills
D and Dunn D. Point-of-care
testing in Aboriginal hands – a model for chronic disease prevention
and management in Indigenous Australia. Point-of-Care: The Journal
of Near-Patient Testing and Technology 2006; 5: 168-176.
Shephard M. Point-of-Care
Testing Trial in General Practice in Australia. Point-of-Care: The
Journal of Near-Patient Testing and Technology 2006; 5: 192.
Shephard M. Analytical
goals for point-of-care testing used for diabetes management in Australian
health care settings outside the laboratory. Point-of-Care: The Journal
of Near-Patient Testing and Technology 2006; 5: 177-185.
Shephard M and Whiting M. Assessment
of the practicability and analytical performance of a point-of-care affinity
chromatography haemoglobin A1c analyser for use in the non-laboratory
setting. Annals of Clinical Biochemistry 2006; 43; 513-515.
2005
Shephard MDS and Gill JP. An
innovative Australian point-of-care model for urine albumin:creatinine
ratio testing that supports diabetes management in indigenous medical
services and has international application. Annals of Clinical Biochemistry
2005; 42:208-215.
Martin D, Shephard M, Freeman H, Jones TW, Davis E and Maguire G.
Point-of-care testing of HbA1c and blood glucose in a remote Aboriginal
Australian community. Medical Journal of Australia 2005; 182: 524-527.
Shephard M, Mazzachi B, Shephard A, McLaughlin K, Barnes G and Denner
B. The
impact of point of care testing on diabetes services along Victoria’s
Mallee Track. Results of a community-based diabetes risk assessment and
management program. Rural and Remote Health 5:371. (On-line), 2005.
2004
Shephard MDS. Point-of-care
testing in the Indigenous Rural Environment – the Australasian Experience.
Chapter 29 p 293-301. In: Point-of-Care Testing. Price C, Hicks J and
St John A (eds). AACC (American Association of Clinical Chemistry) Press,
Washington DC, July 2004.
Shephard MDS. Point-of-care
testing in the Indigenous Rural Community. Clinical Biochemist Newsletter
2004; 153 (June): 26-31.
Shephard MDS. How
to set up and manage a point-of-care testing service. Clinical Biochemist
Newsletter 2004; 153 (June): 36-41.
2003
Shephard MDS and Gill J. Results
of an Innovative Education, Training and Quality Assurance Program for
Point-of-Care HbA1c Testing using the Bayer DCA 2000 in Australian Aboriginal
Community Controlled Health Services. Clinical Biochemist Reviews
2003; 24: 123-131.
Shephard MDS and Mundraby K. Assisting
diabetes management through point-of-care HbA1c testing – the ‘QAAMS’
program for Aboriginal health workers. Aboriginal and Islander Health
Worker Journal 2003; 27 (4): 12-18.
Shephard MDS, Allen GG, Barratt LJ, Paizis K, Brown M, Barbara JAJ, McLeod
G, Vanajek A.Albuminuria
in a remote South Australian Aboriginal community: results of a community-based
screening program for renal disease. Rural and Remote Health 2003;
3 (online) 8 February 2003. Available from http://rrh.deakin.edu.au.
Shephard M. Point-of-care
testing in the Aboriginal community. Australian Journal of Medical
Science 2003; 24: 10-16.
2002
Jones R, Mazzachi B, Shephard M. Point-of-Care
in Aboriginal Hands. Aboriginal and Islander Health Worker Journal
2002; 26 (6): 13-16.
Zeunert S, Cerro N, Boesch L, Duff M, Shephard MDS, Jureidini KF and
Braun J. Nutrition
project in a remote Australian Aboriginal community. Journal of Renal
Nutrition 2002; 12: 102-106.
Shephard MDS and Tallis G. Assessment
of the point-of-care Cholestech Lipid Analyser for lipid screening in
Aboriginal communities. Australian Journal of Medical Science 2002;
23: 4-10.
2001
Shephard MDS and Allen GG. Screening
for renal disease in a remote Aboriginal community using the Bayer DCA
2000. Australian Journal of Medical Science 2001; 22: 164-170.
2000
Shephard MDS, Brown M, Hudson M, Riessen C and Braun J. The
Umoona Kidney Project. Aboriginal and Islander Health Worker Journal
2000; 24 (2): 12-15.
1999
Shephard
MDS, Barratt L, Simpson-Lyttle W. Is the Bayer DCA 2000 acceptable as
a screening instrument for the early detection of renal disease? Annals
of Clinical Biochemistry 1999; 36: 393-394.
Mark Shephard delivering a lecture at the
6th International Conference on Diabetes in Indigenous Peoples.
Cairns, Qld, 2004
|
Mark Shephard presenting the AACB Regional
Travelling Lecture in Bunbury, WA, 2005
|